SPOTLIGHT: Bradley licenses experimental gel

Bradley Pharmaceuticals has agreed to license BioSante's experimental gel for hot flashes for $3.5 million up front and up to $10.5 million in milestones. The FDA is expected to issue a final ruling on Bio-E-Gel in December. Article

Suggested Articles

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.